The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer.
AuthorsFayers, P M
Leonard, R C F
Wilkinson, Peter M
McAllister, E J
Redman, C W E
Scott, I V
Slevin, M L
Roulston, J E
AffiliationMRC Cancer Trials Office, Cambridge CB2 2BB, Dept. of Medical Oncology, Charing Cross Hospital, London W6 8RF, Dept. of Oncology, Western General Hospital, Edinburgh EH4 2XU, Dept. of Oncology, Christie Hospital, Manchester M20 9BX, Dept. Obstet. & Gynaecol, Aberdeen Maternity Hospital, Aberdeen AB9 2ZA, Dept. of Biochemistry and Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, Dept. Obstetrics and Gynaecol, North Staffordshire Royal Infirmary, Stoke-on-Trent ST4 7LN, Clinical Oncology Unit, Bradford Royal Infirmary, Bradford BD9 6RJ, Dept. Obstetrics and Gynaecology, Derby City Hospital, Derby DE3 3NE, Dept. of Oncology, Homerton Hospital, London E9 6SR, Department of Clinical Biochemistry, Royal Infirmary, Edinburgh EH3 9YW, UK.
MetadataShow full item record
AbstractA number of studies have suggested that serum CA 125 levels may be an important prognostic factor for survival of patients with ovarian carcinoma. We investigated, in a large group of patients from 11 UK centers, which combination of CA 125 measurements provided the best prognostic index, and whether the predictive power could be improved by the addition of other factors. Analysis of the data from 248 patients showed that the absolute value of the third CA 125 sample was the single most important factor for predicting progression at 12 months, with the addition of residual bulk only slightly improving the predictive power. Seventy-four patients had CA 125> 70, and of these 57% were correctly predicted to progress or die within 12 months, but 43% remained alive and progression free. The best predictor for progression produced a false positive rate of 19%. We therefore conclude that prognostic information based upon CA 125 measurements up to the start of the third course of initial chemotherapy is not accurate enough to be used to manage individual patients.
CitationThe prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. 1993, 3 (5):285-292 Int. J. Gynecol. Cancer
JournalInternational Journal of Gynecological Cancer
- The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
- Authors: Gadducci A, Cosio S, Fanucchi A, Negri S, Cristofani R, Genazzani AR
- Issue date: 2004 Apr
- Prognostic value of CA 125 in advanced ovarian cancer.
- Authors: Mogensen O
- Issue date: 1992 Mar
- Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
- Authors: Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R
- Issue date: 1995 Jul
- The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients.
- Authors: Steffensen KD, Waldstrøm M, Brandslund I, Petzold M, Jakobsen A
- Issue date: 2012 Nov
- Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
- Authors: Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB
- Issue date: 2008 Jun